MDRNA signs licensing agreement with Roche

April 2009
PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18
Market Research Report
The article reports on the signing of a licensing agreement by MDRNA Inc. and Roche Pharmaceuticals. The licensing agreement is consistent to which Roche will get a non-exclusive license to a portion of MDRNA's technology platform for the development of ribonucleic acid interference-based therapeutics. According to Michael French, president and chief executive of MDRNA, the licensing agreement will offer them resources to continue to pursue multiple, nonexclusive research collaborations.


Related Articles

  • MDRNA Soars on siRNA Tech Deal with Novartis.  // Bioworld Week;3/30/2009, Vol. 17 Issue 13, p3 

    The article reports on the increase in stocks of the Washington-based pharmaceutical company MDRNA Inc. on a deal with the Swiss drugmaker Novartis AG for its gene-silencing small interfering RNA (siRNA) delivery technology for $7.25 million. It notes that the stock of MDRNA Inc. raised by 59%...

  • Roche pulls out of alliance with Basilea for new antibiotic.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p17 

    Reports on the strategic alliance of Roche Pharmaceutical Co. with Basilea Pharmaceutica Ltd. for the development of new antibiotic drug. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for pharmaceutical biotechnology industry.

  • life sciences In Brief.  // Chemical Market Reporter;1/17/2005, Vol. 267 Issue 3, p14 

    The article presents news on various developments in the pharmaceutical industry. The article reports that Antisoma PLC, a Great Britain-based cancer drug development company, will acquire US-based Aptamera Inc. in a share-based transaction, valued at roughly £11.5 million. As part of the...

  • Bayer: respiratory divestment signals strategic strengthening.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p16 

    This article focuses on the newly formed licensing agreement between Bayer Corp. and the pharmaceutical company, Roche. According to this agreement, Bayer had to acquire Roche's OTC business for $2.5 billion sparked speculation that the company is moving away from its historical focus on the...

  • Roche and Maxygen in Interferon Deal. Krause, Carey // Chemical Market Reporter;6/2/2003, Vol. 263 Issue 22, p11 

    Reports that Roche Holding AG has signed a multi-million agreement with Maxygen Inc. to license its next generation interferons to treat hepatitis. Terms of the strategic deal; Benefits of the agreement for both companies; Expectations from Roche's hepatitis portfolio in 2004; Drugs in...

  • PHARMA: OTHER NEWS TO NOTE.  // BioWorld Today;2/24/2014, Vol. 25 Issue 36, p10 

    This section offers news briefs in the pharmaceutical industry including a licensing agreement between Roche AG and Sysmex Inostics GmbH for emPCR portfolio of patents, and a positive opinion for Duoresp Spiromax inhalation powder from the European Committee for Medicinal Products for Human Use.

  • Roche Grows Position in Japan.  // Chemical Market Reporter;12/22/2003, Vol. 264 Issue 22, p10 

    Reports on the expansion of operations of pharmaceutical company, Roche in Japan. Market trends; Drug launches and approvals; Business growth strategy by Roche; Licensing agreement signed by Chugai and Roche that will grant Chugai development and marketing rights in Japan for two cancer drugs.

  • Roche fights to keep Tamiflu blockbuster. Kumar, Rajesh // New Zealand Doctor;7/27/2005, p27 

    Reports on the effort of Swiss pharmaceutical Roche to retain control over its holding, Tamiflu, following threats from the drug's U.S. inventor Gilead, to suspend its licensing agreement, in 2005. Rights sold by Gilead to Roche through a licensing agreement in 1996; Reason Gilead planned to...

  • Report from: India. Nair, A. // Pharmaceutical Technology;Mar2008, Vol. 32 Issue 3, p20 

    The article reports on the conflict of patents among pharmaceutical companies which had developed drugs for severe diseases like AIDS and lung cancer in India. One of the biggest companies involved in the issue is Roche AG which charged Cipla Ltd. of infringing the patent for the lung cancer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics